Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
James Michael Brimson, Sirikalaya Brimson, Chanichon Chomchoei & Tewin Tencomnao. (2020) Using sigma-ligands as part of a multi-receptor approach to target diseases of the brain. Expert Opinion on Therapeutic Targets 24:10, pages 1009-1028.
Read now
Read now
Cornelis J Van der Schyf. (2011) The use of multi-target drugs in the treatment of neurodegenerative diseases. Expert Review of Clinical Pharmacology 4:3, pages 293-298.
Read now
Read now
Cornelis J Van der Schyf, Shunit Gal, Werner J Geldenhuys & Moussa BH Youdim. (2006) Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases. Expert Opinion on Investigational Drugs 15:8, pages 873-886.
Read now
Read now
Alpaslan Ersoy. (2006) Current and future antihypertensive drugs in post-transplant hypertension and related patents. Expert Opinion on Therapeutic Patents 16:8, pages 1093-1106.
Read now
Read now
Théophile Godfraind. (2006) Calcium-channel modulators for cardiovascular disease. Expert Opinion on Emerging Drugs 11:1, pages 49-73.
Read now
Read now
Articles from other publishers (11)
Sucharita Das & Soumalee Basu. 2019. Multi-Target Drug Design Using Chem-Bioinformatic Approaches. Multi-Target Drug Design Using Chem-Bioinformatic Approaches
367
383
.
Raghu Raj, Kirkwood M. Land & Vipan Kumar. (2015) 4-Aminoquinoline-hybridization en route towards the development of rationally designed antimalarial agents. RSC Advances 5:101, pages 82676-82698.
Crossref
Crossref
Caroline Nguyen & Angela Cheng-Lai. (2013) The Polypill. Cardiology in Review 21:1, pages 49-54.
Crossref
Crossref
Michael J. Jamieson, Harvey S. Hecht & Morteza Naghavi. 2011. Asymptomatic Atherosclerosis. Asymptomatic Atherosclerosis
635
647
.
F. Malekzadeh, T. Marshall, A. Pourshams, M. Gharravi, A. Aslani, A. Nateghi, M. Rastegarpanah, M. Khoshnia, S. Semnani, R. Salahi, G. N. Thomas, B. Larijani, K. K. Cheng & R. Malekzadeh. (2010) A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy (‘polypill’) on cardiovascular risk factors. International Journal of Clinical Practice 64:9, pages 1220-1227.
Crossref
Crossref
Liming Shao, Fengjiang Wang, Michael C. Hewitt & Timothy J. Barberich. (2009) μ-Opioid/5-HT4 dual pharmacologically active agents—Efforts towards an effective opioid analgesic with less GI and respiratory side effects (Part I). Bioorganic & Medicinal Chemistry Letters 19:19, pages 5679-5683.
Crossref
Crossref
Antonio Guglietta & Marta Guerrero. (2008) Issues to consider in the pharmaceutical development of a cardiovascular polypill. Nature Clinical Practice Cardiovascular Medicine 6:2, pages 112-119.
Crossref
Crossref
Zafar H Israili, Badiâa Lyoussi, Rafael Hernández-Hernández & Manuel Velasco. (2007) Metabolic Syndrome: Treatment of Hypertensive Patients. American Journal of Therapeutics 14:4, pages 386-402.
Crossref
Crossref
Cornelis J. Van der Schyf, Werner J. Geldenhuys & Moussa B. H. Youdim. (2006) Multifunctional drugs with different CNS targets for neuropsychiatric disorders. Journal of Neurochemistry 99:4, pages 1033-1048.
Crossref
Crossref
Roy Blank. (2006) Amlodipine/atorvastatin single pill for the management of hypertensive patients with additional cardiovascular risk factors. Future Cardiology 2:2, pages 145-159.
Crossref
Crossref
Richard MorphyZoran Rankovic. (2005) Designed Multiple Ligands. An Emerging Drug Discovery Paradigm. Journal of Medicinal Chemistry 48:21, pages 6523-6543.
Crossref
Crossref